ENSEMBLE Covid-19 vaccine trial : Johnson & Johnson (J&J) has launched a multi-nation phase 3 trial called ENSEMBLE for its JNJ-78436735 Covid-19 vaccine candidate (Ad26.COV2.S), which is being developed by its subsidiary – Janssen Pharmaceutical Companies. The US healthcare giant said that the ENSEMBLE vaccine trial has been initiated following positive interim results from its […]
J&J acquisition of Momenta Pharmaceuticals : US healthcare giant Johnson & Johnson (J&J) has signed a $6.5 billion deal to acquire Momenta Pharmaceuticals, a biotech company based in Cambridge, Massachusetts, which is focused on developing drugs for the treatment of rare immune-mediated diseases. As per the terms of the all-cash transaction, shareholders of Momenta Pharmaceuticals […]
Johnson & Johnson (J&J) said that its subsidiary Janssen Pharmaceutical has agreed to manufacture and supply 100 million doses of its SARS-CoV-2 investigational vaccine Ad26.COV2.S to the US government, in a deal worth more than $1 billion. The Janssen Covid-19 vaccine candidate will be supplied either after approval by the US Food and Drug Administration […]
Johnson & Johnson said that it has selected a lead coronavirus vaccine candidate from constructs it has been working on since the start of this year, which it aims to bring it to the market in early 2021 through emergency use authorization. The company, in this connection, said that its subsidiary Janssen Pharmaceutical has significantly […]
J&J takeover of Verb Surgical : Johnson & Johnson (J&J) has agreed to take full ownership in US robotic surgery company Verb Surgical by acquiring the remaining stake it previously did not own from its joint venture partner Verily Life Sciences, an Alphabet company. The joint venture for the development of surgical robotic systems was […]
Janssen Biotech acquisition of bermekimab: Janssen Biotech, a Janssen Pharmaceutical Company of Johnson & Johnson, has agreed to acquire all rights to bermekimab, an investigational compound for certain skin disorders, from XBiotech, in a deal worth up to $1.35 billion, as per the latest pharma acquisition news. Bermekimab, which is an anti-IL-1alpha monoclonal antibody (mAb), […]
Stelara FDA approval for ulcerative colitis treatment : The Janssen Pharmaceutical Companies of Johnson & Johnson has bagged approval from the US Food and Drug Administration (FDA) for Stelara (ustekinumab) for the treatment of moderately to severely active ulcerative colitis. Considered to be a serious, chronic and progressive immune-mediated inflammatory disease of the large intestine, […]
Xarelto FDA approval : The Janssen Pharmaceutical Companies of Johnson & Johnson has secured approval from the US Food and Drug Administration (FDA) for Xarelto (rivaroxaban) for the prevention of venous thromboembolism or blood clots in acutely ill medical patients. The latest approval for the drug is for the treatment of blood clots in hospitalized […]
Ponesimod OPTIMUM trial results : Johnson & Johnson’s Janssen Pharmaceutical said that the phase 3 OPTIMUM clinical trial evaluating ponesimod yielded positive results compared to Aubagio (teriflunomide) in adults having relapsing multiple sclerosis (MS). The OPTIMUM clinical trial, which enrolled 1,133 participants, assessed the efficacy and safety of the selective sphingosine-1-phosphate receptor 1 (S1P1) modulator […]
Johnson & Johnson’s Janssen Pharmaceutical said that its IL-23 p19 inhibitor TREMFYA (guselkumab) met the primary endpoints of American College of Rheumatology 20% improvement (ACR20) in two phase 3 trials in adults with active psoriatic arthritis. Safety profiles observed for guselkumab in the two trials – DISCOVER 1 and 2 were in line with its […]